Page 439 - Read Online
P. 439

Klaas et al. J Cancer Metastasis Treat 2023;9:23  https://dx.doi.org/10.20517/2394-4722.2022.125  Page 13 of 15

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2023.


               REFERENCES
               1.       Molecular subtypes of breast cancer. Available from: https://www.breastcancer.org/types/molecular-subtypes [Last accessed on 13
                   June 2023].
               2.       Breast cancer molecular subtypes |CTCA| city of hope. Available from: https://www.cancercenter.com/cancer-types/breast-cancer/
                   types/breast-cancer-molecular-types [Last accessed on 13 June 2023].
               3.       Kulukian A, Lee P, Taylor J, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in
                   combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther 2020;19:976-87.  DOI
               4.       Most common molecular subtypes of breast cancer |CTCA|. Available from: https://www.cancercenter.com/cancer-types/breast-
                   cancer/types/breast-cancer-molecular-types [Last accessed on 13 June 2023].
               5.       Inic Z, Zegarac M, Inic M, et al. Difference between luminal a and luminal b subtypes according to Ki-67, tumor size, and
                   progesterone receptor negativity providing prognostic information. Clin Med Insights Oncol 2014;8:107-11.  DOI  PubMed  PMC
               6.       Ngamcherdtrakul W, Bejan DS, Cruz-Muñoz W, et al. Targeted nanoparticle for co-delivery of HER2 siRNA and a taxane to mirror
                   the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis. Small 2022;18:e2107550.  DOI  PubMed
                   PMC
               7.       Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res
                   2008;10:R20.  DOI  PubMed  PMC
               8.       Wang Y, Ye F, Liang Y, Yang Q. Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. Br J
                   Cancer 2021;125:1056-67.  DOI  PubMed  PMC
               9.       Ding X, Ray Chaudhuri A, Callen E, et al. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. Nat Commun
                   2016;7:12425.  DOI  PubMed  PMC
               10.      Purrahman D, Mahmoudian-Sani MR, Saki N, Wojdasiewicz P, Kurkowska-Jastrzębska I, Poniatowski ŁA. Involvement of
                   progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine 2022;151:155803.  DOI  PubMed
               11.      Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with
                   amplification of the HER-2/neu oncogene. Science 1987;235:177-82.  DOI  PubMed
               12.      Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. Trastuzumab deruxtecan (DS-8201a): the
                   latest research and advances in breast cancer. Clin Breast Cancer 2021;21:e212-9.  DOI  PubMed
               13.      Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med
                   2022;386:1143-54.  DOI
               14.      Ji C, Li F, Yuan Y, et al. Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastatic breast cancer after
                   tyrosine kinase inhibitors treatment. Oncologist ;2023:oyad127.  DOI
               15.      Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol 2020;47:259-69.  DOI
                   PubMed
               16.      Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2012;2:62.  DOI  PubMed
                   PMC
               17.      Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive
                   early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017;389:1195-205.  DOI  PubMed  PMC
               18.      Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast cancer. BioDrugs 2016;30:75-86.
                   DOI  PubMed
               19.      Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014;23:128-36.  DOI
                   PubMed  PMC
               20.      Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.  DOI  PubMed
               21.      Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res
                   2020;22:61.  DOI  PubMed  PMC
               22.      Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol 2019;20:82.  DOI  PubMed
               23.      Won KA, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (review). Int J Oncol 2020;57:1245-61.
                   DOI  PubMed  PMC
               24.      Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in
                   US women, 2000-2012. JAMA 2018;319:154-64.  DOI  PubMed  PMC
               25.      Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016;293:247-69.  DOI  PubMed
               26.      O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med
                   2011;364:205-14.  DOI
   434   435   436   437   438   439   440   441   442   443   444